CG Oncology reported third quarter 2026 results with revenue of US$1.6 million and a net loss of US$56.89 million, alongside higher basic and diluted loss per share from continuing operations compared with the prior year period.
Across the first nine months of 2026, CG Oncology produced US$3.84 million in revenue but recorded a US$196.15 million loss, highlighting the cash intensive profile of late stage oncology development and an early commercial build.
We now assess how CG Oncology's widening net losses shape the investment narrative that had focused heavily on cretostimogene's potential.
Compare CG Oncology's high burn profile with other late stage biotech plays by scanning our hand picked 21 high quality undiscovered gems that pair meaningful pipelines with stronger fundamentals.
To own CG Oncology, you need to believe cretostimogene progresses through late stage trials and turns the current cash intensive model into a commercial business. The latest results keep that high burn front and center. A US$56.89 million quarterly loss and US$196.15 million loss year to date raise the bar on execution without clearly changing the near term trial or regulatory path.
The key near term catalyst still sits with clinical and regulatory decisions around cretostimogene. The biggest immediate risk is operational strain if expenses stay high without clear efficiency gains. Widening losses underline that risk but do not on their own alter the core thesis, as long as timelines and development plans stay intact.
Against this backdrop, the third quarter 2026 earnings print is the announcement that matters most for now. Revenue of US$1.6 million and basic loss per share from continuing operations of US$0.64 provide a current snapshot of how far CG Oncology is from self funding its pipeline and early commercial build.
The nine month figures show a similar pattern. Revenue of US$3.84 million against a US$196.15 million loss highlights the scale of investment required ahead of wider cretostimogene use. For catalysts like the PIVOT-006 and planned BCG exposed Phase 3 programs to have the potential to create value for shareholders, management will need to balance that spend with tighter operating discipline.
What Current Forecasts Assume About CG Oncology
Analysts are effectively asking you to underwrite a very sharp swing in CG Oncology's financial profile over the next few years. The consensus framework ties cretostimogene execution to aggressive revenue expansion, a move from deep losses into positive earnings, and a rich valuation multiple compared with many other biotech stocks.
On the top line, the current models point to very large yearly revenue growth of 372.9% over the next three years. That pace, if delivered, would take CG Oncology from an early commercial base to the US$658.8 million revenue level that analysts reference by 2029. The projections assume that wider cretostimogene use across non muscle invasive bladder cancer segments is the main driver of that step change in sales.
Profitability assumptions are just as ambitious. Forecasts move profit margins from a starting point of a 3,602.7% loss margin today to a positive 12.9% margin in three years. To get there, the models effectively assume that fixed costs are absorbed across a much larger revenue pool and that the lean commercial build and manufacturing scale up translate into better operating leverage over time.
On earnings, the same analyst set expects a move from a current loss of US$224.4 million to US$85.1 million of earnings by 2029, based on the latest Simply Wall St report. That is a swing of about US$309.5 million. Even within that consensus, the range is wide, with the most optimistic forecast at US$103.3 million of earnings and the most cautious view still showing a loss of US$407.6 million.
The valuation bridge embeds these operating targets into a specific multiple. To line up with the US$91.08 consensus price target, analysts model CG Oncology trading on a P/E of 144.2x those US$85.1 million 2029 earnings. That compares with a current P/E of 29.5x on loss making results and an 18.1x multiple for the broader US biotech industry in the same dataset.
CG Oncology's narrative projects US$658.8 million revenue and US$85.1 million earnings by 2029. This setup assumes very large 372.9% yearly revenue growth and an earnings increase of about US$309.5 million from a current loss of US$224.4 million.
Those projections sit alongside expectations for some shareholder dilution. Analyst models build in 7.0% yearly growth in the share count over the next three years as the business funds its pipeline and commercial rollout. Any change in capital raising plans, such as larger equity issues or a shift toward debt, would affect per share earnings outcomes relative to the current consensus.
Price targets in the current research set cluster around that US$91.08 figure but with meaningful disagreement. The most bullish target is US$108.0 per share and the most cautious is US$79.0. With the stock at US$74.62 as of the latest snapshot in the report, the midpoint target sits 18.1% above the referenced trading level. This gives a sense of how much faith these models place in cretostimogene's commercial rollout and the margin recovery story.
For anyone weighing CG Oncology against other late stage biotech stocks, the key question is comfort level with these embedded assumptions. The revenue ramp, the margin swing, the premium P/E and the required step up in earnings all rest on clinical progress, regulatory approvals and clean commercial execution. Treat the consensus as one scenario, not a forecast, and compare it with your own expectations before relying on it too heavily.
Uncover why CG Oncology's fair value indicates a 41% potential upside to its current price, a discount that could narrow more quickly than many expect.
Three fair value views from the Simply Wall St Community range from about US$91.08 to an extreme US$528.96, with no estimates in the mid buckets. That spread reflects very different readings of CG Oncology's late stage profile, especially around pricing pushback, operating efficiency and the impact of upcoming cretostimogene trial milestones.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your CG Oncology research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
See our latest analysis for CG Oncology. The report includes a comprehensive fundamental analysis summarized in a single visual called the Snowflake, making it easy to evaluate CG Oncology's overall financial health at a glance.
Looking For More Investment Ideas Beyond CG Oncology?
If CG Oncology has sharpened your thinking about risk, reward and runway, it can help to line it up against a broader watchlist. The Simply Wall St Screener gives you a structured way to scan for other opportunities that better match your tolerance for volatility, capital needs and balance sheet strength.
If you want potential upside without stretching too far on quality, start with companies that combine robust financials with share prices that still imply a discount by reviewing the 42 high quality undervalued stocks.
For readers who care more about staying on the defensive side of the spectrum, focus on businesses with steadier profiles and fewer red flags by checking the 32 resilient stocks with low risk scores.
Income focused investors can round out this kind of higher risk biotech exposure with stocks that prioritize returning cash to shareholders through regular payouts by scanning a curated 6 dividend fortresses.
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies
Bailey is an Equity Analyst at Simply Wall St with 4 years of experience as an Associate Adviser at Baywealth Financial Group, where he helped with client portfolio management, investment strategy and research. He completed a Bachelor of Commerce majoring in Finance from the University of Western Australia. As an equity analyst, Bailey provides the team with valuable insights, helping guide the creation of article content and new features like Narratives.
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.